NCT05940324

Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: Stanford University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to understand how ketamine works in the brain to bring about a reduction in OCD symptoms.

Detailed description

The proposed mechanistic trial would be the first to probe the role of ketamine's opioid properties in modulating fronto-striatal circuitry and bringing about reduction of OCD symptoms.

Conditions

• Obsessive-Compulsive Disorder

Interventions

Type	Name	Description
DRUG	Ketamine	Ketamine is an FDA-approved dissociative anesthetic.
DRUG	Naltrexone Pill	Naltrexone is an oral opioid antagonist approved by the Food and Drug Administration (FDA) to treat both alcohol use disorder (AUD) and opioid use disorder (OUD)
OTHER	Placebo pill	An oral inactive placebo pill will be administered to preserve the blinded nature of the study.

Timeline

• Start date: 2024-02-24
• Primary completion: 2028-11-01
• Completion: 2028-11-01
• First posted: 2023-07-11
• Last updated: 2024-12-19

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study